Oncology Models for Predictive Drug Development
Patient-Derived Xenograft (PDX) Models for Precision Oncology
Medicilon’s PDX Models
Medicilon’s Patient-Derived Xenograft (PDX) Models offer an advanced preclinical platform for oncology drug discovery. By implanting patient-derived tumor tissues into immunodeficient mice, these models closely mimic human cancers, retaining their genetic, histological, and molecular properties. This clinically relevant approach enhances the accuracy of predicting drug responses, making PDX models a powerful tool for precision oncology.
High Clinical Relevance
Retains tumor heterogeneity, closely mirroring patient tumor progression and drug response.
Improved Translational Predictability
Enhances the likelihood of clinical success by accurately modeling patient-specific responses.
Longitudinal Tumor Evolution Studies
Enables real-time tracking of tumor evolution, resistance mechanisms, and biomarker identification.
Diverse Tumor Panel
Includes a broad spectrum of cancer types, allowing for personalized medicine approaches.
Immuno-Oncology Integration
Can be combined with immuno-oncology studies and humanized models to assess immune checkpoint inhibitors and other therapies.
Applications of PDX Models in Oncology Research
- Drug Efficacy Testing – Evaluate the therapeutic potential of small molecules, biologics, and combination treatments in a clinically relevant setting.
- Mechanisms of Resistance Analysis – Identify tumor adaptation strategies, helping researchers develop next-generation therapies.
- Biomarker Discovery & Precision Medicine – Correlate molecular profiles with treatment responses, advancing personalized oncology.
- Co-Clinical Trials – Use PDX models to simulate real-world patient responses, bridging the gap between preclinical and clinical research.
Colon Cancer
Lung Cancer
Digestive system disease
Breast Cancer disease
Liver diseases
Pancreatic & immune disease
Urinary disease models
Lymphoma disease models
Ovarian disease models
Head & Neckdisease models
Extensive PDX Model Portfolio
Available PDX Models:
Medicilon provides a diverse selection of PDX models representing multiple cancer types, ensuring a comprehensive approach to precision oncology research.
Cancer Type
Cell Line
- Colon Cancer
- Lung Cancer
- Gastric Cancer
- Breast Cancer
- Liver Cancer
- Pancreatic Cancer
PDXM-221Pa, PDXM-222Pa, PDXM-223Pa
- Urinary Bladder Cancer
PDXM-232U, PDXM-233U, PDXM-234U, PDXM-235U
- Lymphoma & Leukemia
PDXM-242Le, PDXM-242Ly
- Ovarian Cancer
PDXM-271O, PDXM-272O
- Head & Neck Cancer
PDXM-281T, PDXM-282T
PDX model studies to accelerate drug discovery
Comprehensive Oncology Solutions with An Integrated Approach
Medicilon provides a rich portfolio of preclinical oncology models, including CDX and Orthotopic Models, to support every stage of cancer drug development. We adopt an integrated approach by utilizing the same PDX models and/or their corresponding cell lines across multiple drug screening platforms. This multi-platform strategy enhances data consistency, allowing researchers to compare drug responses across in vitro, ex vivo, and in vivo models for a more predictive and translational evaluation of therapeutic efficacy.
Tumor Models
Non-tumor Models
Ocular Disease Models
Ophthalmic disease models for specialized research
Animal models for:
Conjunctival tissue proliferation and NV
Diabetic retinopathy (DR)
Choroidal neovascularization (CNV) and subretinal fibrosis
Corneal neovascularization (Corneal NV)
Acute ocular inflammation models
Dry Eye
